⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887724 | 0.86 | GSK3A (0.33) | — | |
| SCHEMBL29291735 | 0.85 | — | — | |
| SCHEMBL28142411 | 0.74 | — | — | |
| SCHEMBL27689424 | 0.69 | ALDH1A1 (0.37) | — | |
| SCHEMBL6156232 | 0.67 | GSK3A (0.32) | — | |
| SCHEMBL11724475 | 0.67 | — | — | |
| SCHEMBL26292 | 0.66 | — | — | |
| SCHEMBL2553004 | 0.64 | — | — | |
| SCHEMBL11206014 | 0.64 | — | — | |
| SCHEMBL8722677 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853618-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2006093987-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| CN-101421261-B | Tetracyclic steroid derivatives useful as progesterone receptor modulators | JANSSEN PHARMACEUTICA NV | 2013-01-23 | — | — | CN | disclosed |
| CN-101421261-A | Tetracyclic steroid derivatives useful as progesterone receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-29 | — | — | CN | disclosed |
| WO-2009029729-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-1853617-A1 | TRICYCLIC-NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1853618-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006093986-A1 | TRICYCLIC-NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006093987-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1660511-A2 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | Biota, Inc. (AU) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021568-A2 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (AU) | 2005-03-10 | — | — | WO | disclosed |
| WO-2003018546-A2 | TRICYCLIC PYRIDIN-2-ONE ANALOGUES AS LIGANDS FOR GABA-A RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-03-06 | — | — | WO | disclosed |
| EP-1003751-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006410-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5834521-A | TREATMENT OF PROGESTIN MEDIATED MALADIES; OSTEOPOROSIS, CANCER | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-11-10 | — | — | US | disclosed |